Addressing liver fibrosis with liposomes targeted to hepatic stellate cells

Journal of Liposome Research

Volumn 17, Issue 3-4, 2007, Pages 205-218

  Adrian, Joanna E ^a   Poelstra, Klaas ^b   Kamps, Jan A A M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Dilinoleoylphos phatidylcholine; Drug carrier; M6P HSA HVJ liposomes; Mannose 6 phosphate

Indexed keywords

ALPHA TOCOPHEROL; CAMOSTAT MESILATE; CARIPORIDE; COLCHICINE; DILINOLEOYLPHOSPHATIDYLCHOLINE; GLIOTOXIN; HALOFUGINONE; LIPOSOME; LOSARTAN; LUFIRONIL; OXYGENASE INHIBITOR; PENTOXIFYLLINE; QUERCETIN; ROSIGLITAZONE; S 4682; S ADENOSYLMETHIONINE; UNCLASSIFIED DRUG; XIAO CHAI HU TANG;

CONFERENCE PAPER; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENCAPSULATION; EXTRACELLULAR MATRIX; FIBROGENESIS; HUMAN; INFLAMMATION; LIVER CELL; LIVER FIBROSIS; NONHUMAN; PRIORITY JOURNAL; STELLATE CELL;

DRUG CARRIERS; HUMANS; LIPOSOMES; LIVER; LIVER CIRRHOSIS;

EID: 36249009616     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.1080/08982100701528047     Document Type: Conference Paper

References (63)

1. Adrian, J. E., Poelstra, K., Scherphof, G. L., Molema, G., Meijer, D. K. F., Reker-Smit, C., Morselt, H. W., Kamps, J. A. A. M. (2006). Interaction of targeted liposomes with primary cultured hepatic stellate cells: Involvement of multiple receptor systems. J. Hepatol. 44:560-567.
2. Adrian, J.,E., Kamps, J. A. A. M., Scherphof, G. L., Meijer, D. K. F., van Loenen-Weemaes, A. M., Reker-Smit, C., Terpstra, P., Poelstra, K. (2007a). A novel lipid-based drug carrier targeted to the non-parenchymal cells, including hepatic stellate cells, in the fibrotic livers of bile duct ligated rats. Biochim. Biophys. Acta 1768(10):1430-1439.
3. Adrian, J. E., Poelstra, K., Scherphof, G. L., Meijer, D. K. F., van Loenen-Weemaes, A. M., Reker-Smit, C., Morselt, H. W., Zwiers, P., Kamps, J. A. A..M. (2007b). Effects of a new bioactive lipid-based drug carrier on cultured hepatic stellate cells and liver fibrosis in bile duct ligated rats. J. Pharmacol. Exp. Ther. 321:536-543.
4. Adrian, J. E., Kamps, J. A. A. M., Poelstra, K., Scherphof, G. L., Meijer, D. K. F., Kaneda, Y. (2007c). Delivery of viral vectors to hepatic stellate cells in fibrotic livers using HVJ envelops fused with targeted liposomes. J. Drug Target. 15:75-82.
5. Aleynik, S. I., Leo, M. A., Ma, X., Aleynik, M. K., Lieber, C. S. (1997). Polyenylphosphatidylcholine prevents carbon tetrachloride-induced lipid peroxidation while it attenuates liver fibrosis. J. Hepatol. 27:554-561.
6. Allen, T. M., Cullis, P. R. (2004). Drug delivery systems: entering the mainstream. Science 303:1818-1822.
7. Andiran, F., Ayhan, A., Tanyel, F. C., Abbasoglu, O., Sayek, I. (2000). Regenerative capacities of normal and cirrhotic livers following 70% hepatectomy in rats and the effect of alpha-tocopherol on cirrhotic regeneration. J. Surg. Res. 89:184-188.
8. Austin, A. S., Mahida, Y. R., Clarke, D., Ryder, S. D., Freeman, J. G. (2004). A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis. Aliment Pharmacol. Ther. 19:79-88.
9. Bataller, R., Brenner, D. A. (2005). Liver fibrosis. J. Clin. Invest. 115:209-218.
10. Beljaars, L., Molema, G., Schuppan, D., Geerts, A., De Bleser, P. J., Weert, B., Meijer, D. K., Poelstra, K. (2000). Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor. J. Biol. Chem. 275:12743-12751.
11. Beljaars, L., Molema, G., Weert, B., Bonnema, H., Olinga, P., Groothuis, G. M., Meijer, D. K. F., Poelstra, K. (1999). Albumin modified with mannose 6-phosphate: A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells. Hepatology 29:1486-1493.
12. Beljaars, L., Olinga, P., Molema, G., de Bleser, P., Geerts, A., Groothuis, G. M., Meijer, D. K., Poelstra, K. (2001). Characteristics of the hepatic stellate cell-selective carrier mannose 6-phosphate modified albumin (M6P(28)-HSA). Liver 21:320-328.
13. Beljaars, L., Weert, B., Geerts, A., Meijer, D. K. F., Poelstra, K. (2003). The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue. Biochem. Pharmacol. 66:1307-1317.
14. Benyon, R. C., Arthur, M. J. (2001). Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis. 21:373-384.
15. Bickel, M., Baringhaus, K. H., Gerl, M., Gunzler, V., Kanta, J., Schmidts, L., Stapf, M., Tschank, G., Weidmann, K., Werner, U. (1998). Selective inhibition of hepatic collagen accumulation in experimental liver fibrosis in rats by a new prolyl 4-hydroxylase inhibitor. Hepatology 28: 404-411.
16. Bruck, R., Genina, O., Aeed, H., Alexiev, R., Nagler, A., Avni, Y., Pines, M. (2001). Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 33:379-386.
17. Castano, G., Viudez, P., Riccitelli, M., Sookoian, S. (2003). A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients. Ann. Hepatol. 2:36-40.
18. Croquet, V., Moal, F., Veal, N., Wang, J., Oberti, F., Roux, J., Vuillemin, E., Gallois, Y., Douay, O., Chappard, D., Cales, P. (2002). Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. J. Hepatol. 37:773-780.
19. De, B. K., Bandyopadhyay, K., Das, T. K., Das, D., Biswas, P. K., Majumdar, D., Mandal, S. K., Ray, S., Dasgupta, S. (2003). Portal pressure response to losartan compared with propranolol in patients with cirrhosis. Am. J. Gastroenterol. 98:1371-1376.
20. De Bleser, P., J., Jannes, P., Buul-Offers, S. C., Hoogerbrugge, C. M., van Schravendijk, C. F., Niki, T., Rogiers, V., van den Brande, J. L., Wisse, E., Geerts, A. (1995). Insulinlike growth factor-II/mannose 6-phosphate receptor is expressed on CCl4-exposed rat fat-storing cells and facilitates activation of latent transforming growth factor-beta in cocultures with sinusoidal endothelial cells. Hepatology 21:1429-1437.
21. De Bleser, P. J., Niki, T., Rogiers, V., Geerts, A. (1997). Transforming growth factor-beta gene expression in normal and fibrotic rat liver. J. Hepatol. 26:886-893.
22. Dekel, R., Zvibel, I., Brill, S., Brazovsky, E., Halpern, Z., Oren, R. (2003). Gliotoxin ameliorates development of fibrosis and cirrhosis in a thioacetamide rat model. Dig. Dis. Sci. 48:1642-1647.
23. Di Sario, A., Bendia, E., Taffetani, S., Marzioni, M., Candelaresi, C., Pigini, P., Schindler, U., Kleemann, H. W., Trozzi, L., Macarri, G., Benedetti, A. (2003). Selective Na + /H + exchange inhibition by cariporide reduces liver fibrosis in the rat. Hepatology 37:256-266.
24. Friedman, S. L. (2003). Liver fibrosis- from bench to bedside. J. Hepatol. 38: S38-S53.
25. Friedman, S. L., Bansal, M. B. (2006). Reversal of hepatic fibrosis. Fact of fantasy? Hepatology 43:S82-S88.
26. Galli, A., Crabb, D. W., Ceni, E., Salzano, R., Mello, T., Svegliati-Baroni, G., Ridolfi, F., Trozzi, L., Surrenti, C., Casini, A. (2002). Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122: 1924-1940.
27. Gonzalo, T., Talman, E. G., van de Ven, A., Temming, K., Greupink, R., Beljaars, L., Reker-Smit, C., Meijer, D. K., Molema, G., Poelstra, K., Kok, R. J. (2006). Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology. J. Control. Release 111:193-203.
28. Greupink, R., Bakker, H. I., Bouma, W., Reker-Smit, C., Meijer, D. K., Beljaars, L., Poelstra, K. (2006). The antiproliferative drug doxorubicin inhibits liver fibrosis in bile duct-ligated rats and can be selectively delivered to hepatic stellate cells in vivo. J. Pharmacol. Exp. Ther. 317:514-521.
29. Greupink, R., Bakker, H. I., Reker-Smit, C., Loenen-Weemaes, A. M., Kok, R. J., Meijer, D. K., Beljaars, L., Poelstra, K. (2005). Studies on the targeted delivery of the antifibrogenic compound mycophenolic acid to the hepatic stellate cell. J. Hepatol. 43: 884-892.
30. Hagens, W. I., Olinga, P., Meijer, D. K., Groothuis, G. M., Beljaars, L., Poelstra, K. (2006). Gliotoxin non-selectively induces apoptosis in fibrotic and normal livers. Liver Int. 26: 232-239.
31. Harrison, S. A., Torgerson, S., Hayashi, P., Ward, J., Schenker, S. (2003). Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 98:2485-2490.
32. Hasegawa, T., Yoneda, M., Nakamura, K., Makino, I., Terano, A. (2001). Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol. Ther. 15:1667-1672.
33. Heller, J. Trebicka, J., Shiozawa, T., Schepke, M., Neef, M., Hennenberg, M., Sauerbruch, T. (2005). Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis. Liver Int. 25:657-666.
34. Kaneda, Y., Nakajima, T., Nishikawa, T., Yamamoto, S., Ikegami, H., Suzuki, N., Nakamura, H., Morishita, R., Kotani, H. (2002). Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol. Ther. 6:219-226.
35. Kaplan, M. M., Cheng, S., Price, L. L., Bonis, P. A. (2004). A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. Hepatology 39:915-923.
36. Krahenbuhl, L., Lang, C., Ludes, S., Seiler, C., Schafer, M., Zimmermann, A., Krahenbuhl, S. (2003). Reduced hepatic glycogen stores in patients with liver cirrhosis. Liver Int. 23:101-109.
37. Krahenbuhl, L., Talos, C., Reichen, J., Krahenbuhl, S. (1996). Progressive decrease in tissue glycogen content in rats with long-term cholestasis. Hepatology 24:902-907.
38. Lee, E. S., Lee, H. E., Shin, J. Y., Yoon, S., Moon, J. O. (2003). The flavonoid quercetin inhibits dimethylnitrosamine-induced liver damage in rats. J. Pharm. Pharmacol. 55:1169-1174.
39. Lieber, C. S., Robins, S. J., Li, J., DeCarli, L. M., Mak, K. M., Fasulo, J. M., Leo, M. A. (1994). Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology 106:152-159.
40. Lieber, C. S., Weiss, D. G., Groszmann, R., Paronetto, F., Schenker, S. (2003). II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin. Exp. Res. 27:1765-1772.
41. Ma, X., Zhao, J., Lieber, C. S. (1996). Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression. J. Hepatol. 24:604-613.
42. Mato, J. M., Camara,.J., Fernandez de Paz, J., Caballeria, L., Coll, S., Caballero, A., Garcia-Buey, L., Beltran, J., Benita, V., Caballeria, J., Sola, R., Moreno-Otero, R., Barrao, F., Martin-Duce, A., Correa, J. A., Pares, A., Barrao, E., Garcia-Magaz, I., Puerta, J. L., Moreno, J., Boissard, G., Ortiz, P., Rodes, J. (1999). S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J. Hepatol. 30:1081-1089.
43. Matsumura, Y., Sakaida, I., Uchida, K., Kimura, T., Ishihara, T., Okita, K. (1997). Prolyl 4-hydroxylase inhibitor (HOE 077) inhibits pig serum-induced rat liver fibrosis by preventing stellate cell activation. J. Hepatol. 27:185-192.
44. Morgan, T. R., Weiss, D. G., Nemchausky, B., Schiff, E. R., Anand, B., Simon, F., Kidao, J., Cecil, B., Mendenhall, C. L., Nelson, D., Lieber, C., Pedrosa, M., Jeffers, L., Bloor, J., Lumeng, L., Marsano, L., McClain, C., Mishra, G., Myers, B., Leo, M., Ponomarenko, Y., Taylor, D., Chedid, A., French, S., Kanel, G., Murray, N., Pinto, P., Fong, T. L., Sather, M. R. (2005). Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. Gastroenterology 128:882-890.
45. Muriel, P., Moreno, M. G., Hernandez Mdel, C., Chavez, E., Alcantar, L. K. (2005). Resolution of liver fibrosis in chronic CCl4 administration in the rat after discontinuation of treatment: effect of silymarin, silibinin, colchicine and trimethylcolchicinic acid. Basic Clin. Pharmacol. Toxicol. 96:375-380.
46. Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D., Bacon, B. R. (2003). Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38:1008-1017.
47. Nieto, N., Cederbaum, A. I. (2005). S-adenosylmethionine blocks collagen I production by preventing transforming growth factor-beta induction of the COL1A2 promoter. J. Biol. Chem. 280:30963-30974.
48. Nikolaidis, N., Kountouras, J., Giouleme, O., Tzarou, V., Chatzizisi, O., Patsiaoura, K., Papageorgiou, A., Leontsini, M., Eugenidis, N., Zamboulis, C. (2006). Colchicine treatment of liver fibrosis. Hepatogastroenterology 53:281-285.
49. Okuno, M., Akita, K., Moriwaki, H., Kawada, N., Ikeda, K., Kaneda, K., Suzuki, Y., Kojima, S. (2001). Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology 120:1784-1800.
50. Pavanato, A., Tunon, M. J., Sanchez-Campos, S., Marroni, C. A., Llesuy, S., Gonzalez-Gallego, J., Marroni, N. (2003). Effects of quercetin on liver damage in rats with carbon tetrachloride-induced cirrhosis. Dig. Dis. Sci. 48:824-829.
51. Pinzani, M., Gesualdo, L., Sabbah, G. M., Abboud, H. E. (1989). Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J. Clin. Invest. 84:1786-1793.
52. Popov, Y., Patsenker, E., Bauer, M., Niedobitek, E., Schulze-Krebs, A., Schuppan, D. (2006). Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J. Biol. Chem. 281:15090-15098.
53. Raetsch, C., Jia, J. D., Boigk, G., Bauer, M., Hahn, E. G., Riecken, E. O., Schuppan, D. (2002). Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut 50:241-247.
54. Reynaert, H., Thompson, M. G., Thomas, T., Geerts, A. (2002). Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 50:571-581.
55. Sakaida, I., Matsumura, Y., Akiyama, S., Hayashi, K., Ishige, A., Okita, K. (1998). Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. J. Hepatol. 28:298-306.
56. Shimizu, I., Ma, Y. R., Mizobuchi, Y., Liu, F., Miura, T., Nakai, Y., Yasuda, M., Shiba, M., Horie, T., Amagaya, S., Kawada, N., Hori, H., Ito, S. (1999). Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 29:149-160.
57. Sprenger, H., Kaufmann, A., Garn, H., Lahme, B., Gemsa, D., Gressner, A. M. (1999). Differential expression of monocyte chemotactic protein-1 (MCP-1) in transforming rat hepatic stellate cells. J. Hepatol. 30:88-94.
58. Steinbrecher, U. P. (1999). Receptors for oxidized low density lipoprotein. Biochim. Biophys. Acta 1436:279-298.
59. Tuncyurek, P., Sari, M., Firat, O., Mutaf, I., Gulter, C., Tunger, A., Yuce, G., Yilmaz, M., Makay, O., Dayangac, M., Ersin, S. (2006). Does pharmaconutrition with L-arginine and/or alpha-tocopherol improve the gut barrier in bile duct ligated rats? Eur. Surg. Res. 38:4-10.
60. Wright, M. C., Issa, R., Smart, D. E., Trim, N., Murray, G. I., Primrose, J. N., Arthur, M. J., Iredale, J. P., Mann, D. A. (2001). Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 121:685-698.
61. Van de Casteele, M., Roskams, T., Van der Elst, I., van Pelt. J. F., Fevery, J., Nevens, F. (2004). Halofuginone can worsen liver fibrosis in bile duct obstructed rats. Liver Int. 24:502-509.
62. Vial, P., Riquelme, A., Pizarro, M., Solis, N., Madariaga, J. A., Aguayo, G., Duarte, I., Soza, A., Accatino, L., Arrese, M. (2006). Pentoxifylline does not prevent neither liver damage nor early profibrogenic events in a rat model of non-alcoholic steatohepatitis. Ann. Hepatol. 5:25-29.
63. Yang, Y. Y., Lin, H. C., Huang, Y. T., Lee, T. Y., Hou, M. C., Lee, F. Y., Liu, R. S., Chang, F. Y., Lee, S. D. (2002). Effect of 1-week losartan administration on bile duct-ligated cirrhotic rats with portal hypertension. J. Hepatol. 36:600-606.